T

TG Therapeutics
D

TGTX

29.150
USD
-0.69
(-2.31%)
مغلق
حجم التداول
58,210
الربح لكل سهم
1
العائد الربحي
-
P/E
-292
حجم السوق
4,537,644,486
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    B
    BLUE
    -0.31000
    (-3.79%)
    7.86000 USD
    C
    CRVS
    0.20000
    (3.82%)
    5.44000 USD
    I
    INCY
    -1.050
    (-1.43%)
    72.420 USD
    K
    KPTI
    -0.01090
    (-1.60%)
    0.67170 USD
    P
    PBYI
    -0.04500
    (-1.50%)
    2.95500 USD
    المزيد
الأخبار
المقالات

العنوان: TG Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.